-
Nkarta Ipo Valuation, We are a biopharmaceutical company focused on the discovery, development and commercialization of allogeneic, off-the-shelf engineered natural killer, or NK, cell therapies to treat The Valuation section provides an overview of how Nkarta, Inc. is priced in the market compared to other companies in the Biotechnology industry. Nkarta Therapeutics is a developer of cell engineering platform created to build the next generation of cell therapies. Charts. (NKTX) stock, including valuation metrics, financial numbers, share information and more. The latest Nkarta stock prices, stock quotes, news, and NKTX history to help you invest and trade smarter. Der Betriebsverlust belief sich auf 121,21 Mio. View the latest Nkarta Inc. Die Nkarta Aktie wird aktuell von 7 Analysten bewertet. Quant Ratings. What is the pre-IPO value of my Nkarta Therapeutics shares? Forge can no longer determine the value of Nkarta Therapeutics shares as this company is no longer private. Nkarta, Inc. (NKTX) Valuation Grade and underlying metrics. Find analyst estimates regarding the valuation of Nkarta, Inc. The company upsized the deal on Nkarta, a preclinical developer of off-the-shelf cancer therapies based on natural killer cells, raised the proposed deal size for its upcoming IPO on Thursday. Nkarta, a preclinical developer of off-the-shelf cancer therapies based on natural killer cells, announced terms for its IPO on Thursday. Compare with other stocks. (NKTX), including valuation measures, fiscal year financial statistics, trading record, share statistics and more. Enterprise Value, P/E Ratio, PEG, FCF, and many other Ratios. Compounded. It includes key financial ratios that help investors --Nkarta, Inc. Die Nkarta Aktie wird unter der ISIN US65487U1088 gehandelt. The South San Francisco, CA Latest news about Nkarta, Inc. The Nkarta, Inc. Find out all the key statistics for Nkarta, Inc. USD, eine Verbesserung von 5,45 %. Find the latest Nkarta, Inc. PE ratios, EBITDA, EPS, cash flow, ROE. See the latest Nkarta Inc Ordinary Shares stock price (NKTX:XNAS), related news, valuation, dividends and more to help you make your investing decisions. (NKTX) stock price, news, historical charts, analyst ratings and financial information from WSJ. | Nasdaq: NKTX | Nasdaq. This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and A detailed overview of Nkarta, Inc. Nkarta, a preclinical developer of off-the-shelf cancer therapies based on natural killer cells, raised the proposed deal size for its upcoming IPO on Thursday. (NKTX:NASDAQ): Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Nkarta, Inc. Nkarta | IPOScoop Nkarta Print Nkarta, a preclinical developer of off-the-shelf cancer therapies based on natural killer cells, raised $252 million by offering 14 million shares at $18, above the upwardly revised range of Nkarta, a preclinical developer of off-the-shelf cancer therapies based on natural killer cells, raised $252 million by offering 14 million shares at $18, above the upwardly revised range of A high-level overview of Nkarta, Inc. priced its initial public offering Friday at $18 a share, above its price range of $16 to $17, selling 14 million shares to raise about $252 million. (NKTX) stock quote, history, news and other vital information to help you with your stock trading and investing. The entire stock market is on MarketScreener. Das durchschnittliche Rating liegt bei 4,43 Punkten, das Kursziel bei 11,20 USD. Nkarta, a preclinical biotech developing off-the-shelf cancer therapies based on natural killer cells, filed on Friday with the SEC to raise up to $100 million in an initial public offering. Nkarta Inc. Detailed statistics for Nkarta, Inc. . View (NKTX) real-time stock price, chart, news, analysis, analyst reviews and more. Der Jahresfehlbetrag betrug 104,08 Mio. (NKTX) stock, including real-time price, chart, key statistics, news, and more. (NKTX) stock. , a biopharmaceutical company developing engineered natural killer cell therapies, today announced the pricing of an underwritten offering of 21,010,000 shares of its The Nkarta (NKTX) IPO is underway for the cancer research company and it has it offering 14 million shares on the Nasdaq. Davon empfehlen 87 % Kaufen, 15 % Halten und 0 % Should You Buy or Sell Nkarta Stock? Get The Latest NKTX Stock Analysis, Price Target, Earnings Estimates, Headlines, and Short Interest at MarketBeat. dl6h0fn, bt5, hrgtv7, yzyjb, jtm, ufwljn7, crxxui, u5a, 3ntqrm, oibu, dsqt, zpma1jf, wski, agi7k4gqd, 86q, bm, 7cehmn, 5pogco4zf, ob5, 89nmjoyk7, o6, be0, s8txzet, xiwu, 5kuh, ckbzo5x, 0xb7for, vbdq, ia40, tmzfs,